Thisvulnerability has been highlighted by numerous research reports.9−11 Consequently, a new generation of PRMT5 inhibitors employing MTA-cooperativePRMT5 binding has entered clinical trials for the treatment of patientswith MTAP-del cancers AMG 193,28 MRTX1719,29 TNG908,30 and TNG462,31) along with AZD-347032 (structure not shown), that are expected to give an increased therapeuticwindow arising from targeting the MTA:PRMT5 complex; Figure 2. This evidence concerns the gene PRMT5 and cancer.